Anti-Human BTLA/CD272 Reference Antibody (Tifcemalimab, RUO) (HV375016)

Name: Anti-Human BTLA/CD272 Reference Antibody (Tifcemalimab, RUO)
Brand: abinScience
SKU: HV375016
Price: 176 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HV375016
Descripción	Tifcemalimab (HV375016) is a research-grade recombinant antibody targeting CD272. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huésped	Chimeric
Clonalidad	Monoclonal
Isotipo	IgG4-kappa
Sistema de expresión	Mammalian cells
Objetivo	B- and T-lymphocyte attenuator, BTLA, CD272, B- and T-lymphocyte-associated protein
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% purity as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	Q7Z6A9
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4 Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	JS004, Icatolimab, 2236068-83-8
Fondo	B- and T-lymphocyte attenuator (CD272/BTLA) is a ~32 kDa protein. Inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2. May interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14. In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells. 1. Watanabe, N. et al. (2003) Nature immunology 4, 670-9. PMID: 12796776 2. Gavrieli, M. et al. (2003) Biochemical and biophysical research communications 312, 1236-43. PMID: 14652006 3. Sedy, JR. et al. (2005) Nature immunology 6, 90-8. PMID: 15568026 4. Cai, G. et al. (2008) Nature immunology 9, 176-85. PMID: 18193050 5. Cheung, TC. et al. (2009) Journal of immunology (Baltimore, Md. : 1950) 183, 7286-96. PMID: 19915044
Nota	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG4 (S228P) Recombinant Isotype Control Antibody (13R4) (HP298207) Human IgG4 (S228P & L235E) Recombinant Isotype Control Antibody (HyHEL-10) (HP614107) Human IgG4 (S228P) Recombinant Isotype Control Antibody (SAA0184) (HP298107)